Mark Effron, MD
- Sr Physician-Medical Director, Southshore Region
- 1514 Jefferson Hwy, New Orleans, LA, 70121
For additional information or to make an appointment, click here.
Overview
Overview
- Dr. Mark Effron received a Doctor of Medicine degree from The Johns Hopkins University School of Medicine located in Baltimore, MD. He then completed an Internship and Residency in Internal Medicine at Northwestern University in located in Illinois. Following his time as a Resident, Dr. Effron completed a Fellowship in Cardiovascular Diseases at Johns Hopkins as well as the National Institute on Aging, National Institutes of Health. Following training, Dr. Effron joined the faculty of the Johns Hopkins University School of Medicine and served as Director of the Coronary Care Unit and Cardiovascular Research Laboratory at the Sinai Hospital of Baltimore. Subsequently, he entered the pharmaceutical industry where his research continued to focus on the use of drugs affecting blood clotting in the treatment of cardiovascular disease. Following his retirement from the pharmaceutical industry, he joined the Cardiology Department of the Ochsner family. Dr. Effron is board certified by the American Board of Internal Medicine.
Publications
Selected publications
-
2023More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?. Mayo Clinic Proceedings. 98:1590-1592.
-
2023Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. Journal of the American Geriatrics Society. 71:1701-1713.
-
2023Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. Journal of the American Geriatrics Society.
-
2022PRASUGREL OR CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AT DIFFERENT THROMBOTIC RISK: RESULTS FROM THE PROMETHEUS STUDY. European Heart Journal Supplements. 24.
-
2022Racial Disparities and Excess Cardiovascular Mortality Before and During the COVID-19 Pandemic: Time for a Solution. Mayo Clinic Proceedings. 97:2180-2183.
-
2022Proposal for a Simple Algorithmic Approach to Manage Drug-Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients Comment. Seminars in Thrombosis and Hemostasis.
-
2022Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock. Mayo Clinic Proceedings. 97:1041-1043.
-
2022To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Seminars in Thrombosis and Hemostasis.
-
2021Prasugrel or Clopidogrel in Patients With Acute Coronary Syndromes With Multivessel Disease: Results From the PROMETHEUS Study. Journal of the American College of Cardiology. 78:B93-B93.
-
2021Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine.
-
2021Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine.
-
2020Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions. 95:885-892.
-
2020Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clinical Research in Cardiology. 109:725-734.
-
2019Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. Journal of Thrombosis and Thrombolysis. 48:42-51.
-
2019Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study. Catheterization and Cardiovascular Interventions. 93:E204-E210.
-
2019MANAGEMENT OF HIGH ON-TREATMENT PLATELET REACTIVITY TO CLOPIDOGREL, PRASUGREL AND TICAGRELOR IN THE SAME PATIENT. Journal of the American College of Cardiology. 73:2911-2911.
-
2019The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions. 93:E112-E119.
-
2019Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions. 94:53-60.
-
2019Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. International Journal of Cardiology. 275:31-35.
-
2018Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study. Journal of the American Heart Association. 7.
-
2018Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy - "Real World" Experience. Progress in Cardiovascular Diseases. 60:531-536.
-
2018One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database. American Journal of Cardiovascular Drugs. 18:129-141.
-
2018The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease - Where Is the Moon Now?. Progress in Cardiovascular Diseases. 60:457-459.
-
2018The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study. Catheterization and Cardiovascular Interventions. 91:242-250.
-
2017Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention A Report From the PROMETHEUS Study. JACC: Cardiovascular Interventions. 10:2017-2025.
-
2017Associations between Stent Diameter and Clinical Outcomes in ACS PCI Using Second Generation Drug-Eluting Stents: From the PROMETHEUS Study. Journal of the American College of Cardiology. 70:B316-B317.
-
2017Impact of prior cerebrovascular diseases on treatment strategies and clinical outcomes after percutaneous coronary interventions. European Heart Journal. 38:76-76.
-
2017Multivessel Versus Culprit Vessel-Only Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction: Insights From the TRANSLATE-ACS Observational Study. Journal of the American Heart Association. 6.
-
2017Outcomes by Total Stent Length in ACS PCI with Second Generation Drug-Eluting Stents: Results from the PROMETHEUS Study. Journal of the American College of Cardiology. 70:B316-B316.
-
2017Sex-Related Differences in Outcomes Among Men and Women Under 55 Years of Age With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results From the PROMETHEUS Study. Catheterization and Cardiovascular Interventions. 89:629-637.
-
2016Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). Circulation: Cardiovascular Interventions. 9.
-
2016Predictors of optimal medical therapy on discharge after percutaneous coronary intervention for acute coronary syndrome: An analysis of the PROMETHEUS registry. Journal of the American College of Cardiology. 68:B90-B90.
-
2016Prevalence of prasugrel use and associations between type of acute coronary syndrome and 1-year clinical outcomes. Journal of the American College of Cardiology. 68:B42-B42.
-
2016Relationship between anemia, prasugrel use and clinical outcomes in contemporary percutaneous coronary intervention for acute coronary syndromes. Journal of the American College of Cardiology. 68:B44-B45.
-
2016Sex-related differences in outcomes after percutaneous coronary intervention (PCI) in patients with diabetes presenting with acute coronary syndrome (ACS): Results from the PROMETHEUS study. Journal of the American College of Cardiology. 68:B110-B111.